ERBB2 and breast carcinoma: Although in the Early Breast Cancer Trialists’ Collaborative Group overview [24] the relative benefit of polychemotherapy was similar in node-negative and node-positive breast cancer patients, and the absolute benefit of chemotherapy is much greater in women with node-positive disease, axillary lymph node involvement was not synonymous per se of a benefit from chemotherapy in patients with ER-positive, HER2-negative disease.